Effect of Pistacia atlantica on the elimination of Helicobacter pylori and improvement of gastric reflux in patients with chronic cough: A randomized clinical trial

2021 ◽  
Vol 07 ◽  
Author(s):  
Masoud Shirmohammadi ◽  
Milad Asadi ◽  
Venus Zafari ◽  
Yeganeh Khalili ◽  
Habib Zarredar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Helicobacter Pylori ◽  
Chronic Cough ◽  
Intervention Group ◽  
Gastrointestinal Complications ◽  
Pistacia Atlantica ◽  
Stool Samples ◽  
Gastric Reflux ◽  
H Pylori ◽  
Age And Sex

Background: Pistacia atlantica (P. atlantica) has been associated with beneficial medical effects on gastrointestinal complications. Objective: It was intended to assess the effects of P. atlantica in elimination of Helicobacter pylori (H. pylori) infection and amelioration of gastric reflux and chronic cough. Methods: In this clinical trial study, 100 subjects with H. pylori infection who had the symptoms of gastric reflux and chronic cough were recruited and classified into two intervention and placebo groups, continuing 50 subjects each. The intervention group was administered two 500 mg doses of P. atlantica extract each day. The H. pylori antigen load in stool samples was evaluated using ELISA. The severity of cough and gastric re flux was also determined. Results: The subjects in two groups were age and sex matched and the baseline measurements were similar on the day 0. Nonetheless, it was observed that on the day 14, there was a significant reduction of H. pylori antigen load in the intervention group compared with the placebo group (P = 0.00021). Furthermore, the intensity of chronic cough was reduced significantly in the intervention group (P = 0.0014). The gastric reflux was improved in the intervention group at the end of the study. Conclusion: P. atlantica extract was beneficial in controlling H. pylori infection. It also improved the complications of the infection, like gastric reflux and chronic cough. Hence, it is highly recommended to value natural products, along with traditional antibiotics, in ameliorating H. pylori infection.

scholarly journals Atorvastatin and standard treatment of Helicobacter pylori: Single Blinded Randomized Controlled Clinical Trial

2020 ◽  
Author(s):  
Mohammad Reza Mohammad Hoseini Azar ◽  
Parham Portaghali ◽  
Ali Jafari ◽  
Amin Sedokani
Keyword(s):  
Clinical Trial ◽  
Helicobacter Pylori ◽  
Standard Treatment ◽  
Intervention Group ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Bismuth Subcitrate ◽  
Significant Difference ◽  
H Pylori

AbstractBackgroundConsidering the increase in drug resistance over time to Helicobacter pylori treatment relying on the anti-inflammatory and antibacterial effects of atorvastatin to increase the success rate of H. pylori eradication, we examined the effect of adding atorvastatin to standard treatment of H. pylori eradication.Materials and MethodsA total of 186 symptomatic patients who had been diagnosed with Helicobacter pylori infection and tested for H. pylori eradication were examined by a pathological response or positive urea breath test. Patients who received atorvastatin in addition to standard treatment were also identified based on a table of random numbers. Standard treatment included a 240mg bismuth subcitrate tablet, a 40mg pantoprazole tablet, a 500mg metronidazole tablet, and 2 capsules of 500mg amoxicillin, all taken BID for 14 days. After 4 weeks of treatment, all patients underwent stool testing for H. pylori fecal antigen. If the test was positive, the request was considered a failure of treatment, and if the test was negative, it was considered a successful eradication of H. pylori. The clinical trial registration code for this study is IRCT20190823044589N1.ResultsThe eradication rate of H. pylori was 80% in the control group and 80.9% in the intervention group, which did not show a statistically significant difference between the two groups (P-value = 0.971).ConclusionAdding atorvastatin to 4-drug regimen of PPI, bismuth subcitrate, amoxicillin, and metronidazole as the first line of treatment for H. pylori eradication is ineffective.

Good diagnostic accuracy of a chemiluminescent immunoassay in stool samples for diagnosis of Helicobacter pylori infection in patients with dyspepsia

2016 ◽  
Vol 64 (2) ◽  
pp. 388-391 ◽  
Author(s):  
María José Ramírez-Lázaro ◽  
Josep Lite ◽  
Sergio Lario ◽  
Pepa Pérez-Jové ◽  
Antònia Montserrat ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gold Standard ◽  
Rapid Urease Test ◽  
Diagnostic Reliability ◽  
Predictive Values ◽  
Urease Test ◽  
Stool Samples ◽  
H Pylori ◽  
Good Diagnostic Accuracy ◽  
Sensitivity Specificity

Laboratory-based chemiluminescence immunoassays (CLIA) are widely used in clinical laboratories. Some years ago, a CLIA test was developed for the detection of Helicobacter pylori in stool samples, known as LIAISON H. pylori SA, but little information on its use has been reported. To evaluate the accuracy of the LIAISON H. pylori SA assay for diagnosing H. pylori infection prior to eradication treatment. Diagnostic reliability was evaluated in 252 untreated consecutive patients with dyspepsia. The gold standard for diagnosing H. pylori infection was defined as the concordance of the rapid urease test (RUT), histopathology and urea breath test (UBT). The CLIA assay was performed according to the manufacturer's instructions. Sensitivity, specificity, positive and negative predictive values, and 95% CIs were calculated. According to the gold standard selected, 121 patients were positive for H. pylori infection and 131 negative. LIAISON H. pylori SA had a sensitivity of 90.1% and a specificity of 92.4%, with positive and negative predictive values of 91.6% and 90.1%, respectively. The accuracy of the LIAISON H. pylori SA chemiluminescent diagnostic assay seems comparable to that of ELISA or the best-performing LFIAs. Its sensitivity and specificity, however, seem slightly lower than those of histology, RUT or UBT. The advantages of the assay are that it is cheap, automated, and minimally labor-intensive.

scholarly journals The Magnitude and associated factors of Helicobacter pylori infection among adult dyspeptic patients attending Bokoji Hospital, Southeast Ethiopia

2020 ◽  
Author(s):  
Dagaga Goboto Kenea ◽  
Mesfin Negawo ◽  
Firaol Kitila Lemessa ◽  
Solomon Tejineh
Keyword(s):  
Helicobacter Pylori ◽  
Alcohol Drinking ◽  
Intestinal Parasites ◽  
Helicobacter Pylori Infection ◽  
P Value ◽  
Cross Sectional ◽  
Gastrointestinal Complications ◽  
Ulcer Disease ◽  
Southeast Ethiopia ◽  
H Pylori

Abstract Background: Helicobacter pylori infection is the most common chronic bacterial infection and there were approximately 4.4 billion individuals with H pylori infection worldwide. Among those, hundreds of millions of people develop peptic ulcer disease during their lifetime and still tens of millions might progress to gastric cancer. Hence, early information is very important to prevent upper gastrointestinal complications. Consequently, the current study aimed to assess the magnitude and associated risk factors of Helicobacter pylori infection among adult dyspeptic patients attending Bokoji hospital, Southeast Ethiopia.Methods: A hospital-based cross-sectional study involving 348 adult dyspeptic patients attending Bokoji hospital was carried out from July 16 to October 31, 2019. About 50 mg of fresh stool and 60 µl of capillary blood were collected from each dyspeptic patient and analyzed for detection of Helicobacter pylori antigens, presence of intestinal parasites and ABO blood grouping respectively. Data were entered using Epi Info 7 and Statistical analysis was done using SPSS version 21 and a p-value less than 0.05 was considered as statistically significant.Results: The overall magnitude of Helicobacter pylori infection was 47.7%. The magnitude of H. pylori infection was almost two times higher in patients who do not have a habit of handwashing after toilet visit than those who wash their hand's habit of handwashing after visiting toilet (AOR 2.241, 95% CI (1.410, 3.563) and alcohol drinking habit (AOR 1.796, 95% CI (1.087, 2.968). Conclusions: The magnitude of H. pylori was high in the study area and associated with handwashing habits after toilet use and alcohol drinking habits. Therefore, the community could be educated on the handwashing habit to minimize H. pylori infections.

scholarly journals Atorvastatin in Helicobacter Pylori Treatment: A Randomized Controlled Trial and Review

2021 ◽  
Author(s):  
Mohammad Reza Mohammad Hoseini Azar ◽  
Parham Porteghali ◽  
Amin Sedokani
Keyword(s):  
Helicobacter Pylori ◽  
Standard Treatment ◽  
Controlled Trial ◽  
Intervention Group ◽  
Trial Registration ◽  
Control Group ◽  
P Value ◽  
Bismuth Subcitrate ◽  
Significant Difference ◽  
H Pylori

Abstract Background: Considering the increase in drug resistance over time to Helicobacter pylori treatment relying on the anti-inflammatory and antibacterial effects of atorvastatin to increase the success rate of H. pylori eradication, we examined the effect of adding atorvastatin to standard treatment of H. pylori eradication.Results: A total of 186 symptomatic patients who had been diagnosed with Helicobacter pylori infection and tested for H. pylori eradication were examined by a pathological response or positive urea breath test. Patients who received atorvastatin in addition to standard treatment were also identified based on a table of random numbers. Standard treatment included a 240mg bismuth subcitrate tablet, a 40mg pantoprazole tablet, a 500mg metronidazole tablet, and 2 capsules of 500mg amoxicillin, all taken BID for 14 days. After 4 weeks of treatment, all patients underwent stool testing for H. pylori fecal antigen. If the test was positive, the request was considered a failure of treatment, and if the test was negative, it was considered a successful eradication of H. pylori. The clinical trial registration code for this study is IRCT20190823044589N1. The eradication rate of H. pylori was 80% in the control group and 80.9% in the intervention group, which did not show a statistically significant difference between the two groups (P-value=0.971).Conclusion: Adding atorvastatin to 4-drug regimen of PPI, bismuth subcitrate, amoxicillin, and metronidazole as the first line of treatment for H. pylori eradication is ineffective.Trial registration: IRCT, IRCT20190823044589N1. Registered 28 December 2019 - Retrospectively registered, https://en.irct.ir/trial/41734

scholarly journals Role of Helicobacter Pylori in Gastro-Intestinal Tract Disorders (Gitds) Among Patients in Kirkuk City, Iraq

2017 ◽  
Vol 14 (3) ◽  
pp. 1159-1164
Author(s):  
Adil A. Abdul Razaq ◽  
Chateen I. Ali Pambuk ◽  
Yahya J. Salman
Keyword(s):  
Helicobacter Pylori ◽  
Intestinal Tract ◽  
Parasitic Infection ◽  
High Rate ◽  
Parasitic Infections ◽  
Duodenal Ulcers ◽  
Bowel Diseases ◽  
Stool Samples ◽  
H Pylori ◽  
Gastro Intestinal Tract

ABSTRACT: In recent works Helicobacter pylori (H. pylori) become a significant criteria and essential diagnostic tool for studying the etiology of gastro-intestinal tract disorders (GITDs), for this purpose a total of stool samples were collected from 266 patients from both gender ,they were aging from below one year to over than 70 years. Their compliance with epi-gastric pain, diarrhea weigh loose and other disorders. Types of GITDS were detected and classified by the gastro-enterologists in two main Hospitals and from patients attending Private clinics and medical labs in Kirkuk city. H. pylori was detected form stool samples by using rapid lateral immune-chromatography assay (RLICA). GITDs involve, H. pylori positive distributed in 132 (49.62%), followed by 74 (27.81 % ), 59(22.18 %), 7(2.63 %), 3(1.12%) and 2(0.75 %) for irritable bowel diseases, inflammatory bowel diseases, peptic ulcer, ulcerative colitis and duodenal ulcers diseases respectively. Whereas 171, (64.28%) were positive for parasitic infection, P<0.05 .Moreover other 48, (18.04 %) stool samples were non-identified it's about from the described diseases. A total of132 (49.62 %) of H. pylori positive samples were distributed in 46(38.84 %) samples for IBD versus to 41(31.81 %) for IBS and 33(25%) were positive for parasitic infections, p <0.05. According to age; highest rate 10 (55.55 %) of H. pylori was recorded among patients aging from 61 to 70 years, whom they have IBD. Whereas 7 (70 %) have IBS within age group from 41 to 50 years, P <0.05. It can be that H. pylori participate with high rate in GITDs patients particularly IBD elderly patients.

scholarly journals The efficacy, safety, and tolerability of levofloxacin quadruple therapy for helicobacter pylori eradication: a randomized, double-blind clinical trial

2020 ◽  
Author(s):  
Fariborz Mansour-Ghanaei ◽  
Behnam Masihypour ◽  
Mohammad Fathalipour ◽  
Soheil Hassanipour ◽  
Homayoon Sokhanvar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Helicobacter Pylori ◽  
Alternative Therapy ◽  
Double Blind ◽  
Intention To Treat ◽  
Bismuth Subcitrate ◽  
Double Blind Clinical Trial ◽  
End Of Treatment ◽  
H Pylori ◽  
To Receive

Abstract BackgroundThe incidence of microbial resistance is increasing, and new rescue regimens are needed in order to treat Helicobacter pylori (H. pylori) infection. To evaluate the efficacy, safety, and tolerability of levofloxacin based quadruple therapies in the eradication of H. pylori.MethodsIn a randomized, double-blind clinical trial, 220 patients with dyspepsia and H. pylori infection were randomly assigned to receive either bismuth subcitrate 240 mg, pantoprazole 20 mg, amoxicillin 1000 mg twice a day, and levofloxacin 500 mg daily for seven days (BPAL-7), or ten days (BPAL-10). The eradication of H. pylori was evaluated two months after the end of treatment, and adverse drug reactions (ADRs) were assessed during the intervention.ResultsAccording to intention-to-treat and per-protocol, the eradication rate was significantly lower in the BPAL-7 regimen 49.1% (95% CI: 39.3–57.8) and 47.6% (95% CI: 39.7–58.4), respectively compared to the BPAL- 10 regimen 62.7% (95% CI: 53.6–72.8) and 62.4% (95% CI: 55.1–72.8), respectively. The incidence of ADRs was not statistically significant between BPAL-7 (33.6%) and BPAL-10 (36.7%) groups.ConclusionAlthough the ADRs were negligible in both groups, these regimens could not be an ideal alternative therapy for H. pylori because of low eradication rates compared to standard regimens.Trial registration: The study reviewed and approved by the Iranian Registry of Clinical Trials (IRCT201406141155N19). This trial was retrospectively registered on July 10, 2015.

scholarly journals The Efficacy, Safety, And Tolerability of Levofloxacin Quadruple Therapy For Helicobacter Pylori Eradication: A Randomized, Double-Blind Clinical Trial

2021 ◽  
Author(s):  
Fariborz Mansour-Ghanaei ◽  
Behnam Masihypour ◽  
Mohammad Fathalipour ◽  
Soheil Hassanipour ◽  
Homayoon Sokhanvar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Helicobacter Pylori ◽  
Alternative Therapy ◽  
Double Blind ◽  
Intention To Treat ◽  
Bismuth Subcitrate ◽  
Double Blind Clinical Trial ◽  
End Of Treatment ◽  
H Pylori ◽  
To Receive

Abstract The incidence of microbial resistance is increasing, and new rescue regimens are needed in order to treat Helicobacter pylori (H. pylori) infection. To evaluate the efficacy, safety, and tolerability of levofloxacin based quadruple therapies in the eradication of H. pylori. In a randomized, double-blind clinical trial, 220 patients with dyspepsia and H. pylori infection were randomly assigned to receive either bismuth subcitrate 240 mg, pantoprazole 20 mg, amoxicillin 1000 mg twice a day, and levofloxacin 500 mg daily for seven days (BPAL-7), or ten days (BPAL-10). The eradication of H. pylori was evaluated two months after the end of treatment, and adverse drug reactions (ADRs) were assessed during the intervention. According to intention-to-treat and per-protocol, the eradication rate was significantly lower in the BPAL-7 regimen 49.1 % (95 % CI: 39.3-57.8) and 47.6 % (95 % CI: 39.7-58.4), respectively compared to the BPAL- 10 regimen 62.7 % (95 % CI: 53.6-72.8) and 62.4 % (95 % CI: 55.1-72.8), respectively. The incidence of ADRs was not statistically significant between BPAL-7 (33.6 %) and BPAL-10 (36.7 %) groups. Although the ADRs were negligible in both groups, these regimens could not be an ideal alternative therapy for H. pylori because of low eradication rates compared to standard regimens.Trial registration: The study reviewed and approved by the Iranian Registry of Clinical Trials (IRCT201406141155N19).

scholarly journals Seroepidemiology ofHelicobacter pyloriinfection in vegans and meat-eaters

1992 ◽  
Vol 108 (3) ◽  
pp. 457-462 ◽  
Author(s):  
M. J. Webberley ◽  
J. M. Webberley ◽  
D. G. Newell ◽  
P. Lowe ◽  
V. Melikian
Keyword(s):  
Helicobacter Pylori ◽  
Risk Factor ◽  
Campylobacter Jejuni ◽  
Meat Consumption ◽  
Cross Reactivity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibody ◽  
Specific Igg ◽  
H Pylori ◽  
Age And Sex

SUMMARYAn enzyme-linked immunosorbent assay has been used to diagnose serologically the prevalence ofHelicobacter pyloriinfection in Asian life-long vegans. There was no difference in the seropositivity between these individuals and a group of age-and sex-matched Asian meat-eaters, indicating the meat consumption is not a risk factor forH. pyloriinfection. However, both Asian groups had a higher prevalence of infection than age- and sex-matched Caucasian meat-eaters. Additionally, the Asian individuals had a wider range of specific IgG antibody concentrations than the Caucasians. This did not appear to be due to antigenic cross-reactivity betweenH. pyloriandCampylobacter jejuni. The significance of these observations to the establishment of cut-off levels for the serodiagnosis of certain ethnic groups is discussed.

scholarly journals Evaluation of a Monoclonal Antibody-Based Test for Detection of Helicobacter pylori-Specific Antigen in Stool Samples from Mice

2004 ◽  
Vol 11 (4) ◽  
pp. 799-800 ◽  
Author(s):  
Julia Crone ◽  
Erin Symonds ◽  
Fiona Campbell ◽  
Ross Butler
Keyword(s):  
Monoclonal Antibody ◽  
Helicobacter Pylori ◽  
Monoclonal Antibodies ◽  
Sensitivity And Specificity ◽  
Specific Antigen ◽  
Noninvasive Technique ◽  
Helicobacter Felis ◽  
Stool Samples ◽  
H Pylori

ABSTRACT A test using monoclonal antibodies for detection of antigen in stool samples was compared with culture and histology for noninfected (n = 25), Helicobacter pylori-infected (n = 25), and Helicobacter felis-infected (n = 6) mice. Sensitivity and specificity were 96%. The monoclonal antibody-based test is therefore a noninvasive technique that is able to diagnose H. pylori infection in mice.

scholarly journals A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate

2017 ◽  
Vol 55 (8) ◽  
pp. 2400-2405 ◽  
Author(s):  
Erin Beckman ◽  
Ilaria Saracino ◽  
Giulia Fiorini ◽  
Courtney Clark ◽  
Vladimir Slepnev ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Biopsy Sample ◽  
True Positive ◽  
Content Type ◽  
Clarithromycin Resistance ◽  
Urease Test ◽  
Eradication Of Infection ◽  
Stool Samples ◽  
Stool Specimens ◽  
H Pylori

ABSTRACTClarithromycin-based regimens are commonly used as a first-line therapy forHelicobacter pylori-positive patients; however, resistance to clarithromycin has led to treatment failures. The aim of this study was to evaluate the feasibility of using stool samples to detect the presence ofH. pyloriDNA while concurrently detecting mutations associated with resistance to clarithromycin. For this purpose, total DNA was extracted from 294 raw stool specimens fromH. pylori-positive and -negative patients. TaqMan real-time PCR amplification was used to detect the presence ofH. pylorias well as to predict the phenotype of the organism and the related outcome for patients treated with clarithromycin. Clarithromycin resistance was determined upon analysis of the PCR result. Patients were also tested by a urea breath test and were subjected to esophagogastroduodenoscopy, followed by histology, culture, and a rapid urease test, in order to obtain a consensus patient infection status. Of 294 total stool samples, 227 were deemed true positive. The sensitivity ofH. pyloridetection by PCR was 93.8%. Of 213 true-positive samples that were sequenced, 36.2% showed point mutations associated with clarithromycin resistance (A2142C, A2142G, A2143G). The final correlation of the mutant genotypes as determined by sequencing with the eradication of infection was 86%. We found thatHelicobacter pyloriDNA can be detected in human stool specimens with high sensitivity and can therefore be used to determine the presence of the bacterium without obtaining a biopsy sample. Moreover, genotypic resistance to clarithromycin can be predicted without obtaining a biopsy sample, facilitating the choice of the right therapeutic approach.

Sign in / Sign up

Export Citation Format

Share Document